Cargando…
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
Resistance to chemotherapy is a major obstacle to the effective treatment of many tumor types. Although many anticancer therapies can alter tumor growth, in most cases the effect is not long lasting. Consequently, there is a significant need for new agents with low susceptibility to common drug resi...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972556/ https://www.ncbi.nlm.nih.gov/pubmed/21050423 http://dx.doi.org/10.1186/bcr2573 |
_version_ | 1782190808765562880 |
---|---|
author | Rivera, Edgardo Gomez, Henry |
author_facet | Rivera, Edgardo Gomez, Henry |
author_sort | Rivera, Edgardo |
collection | PubMed |
description | Resistance to chemotherapy is a major obstacle to the effective treatment of many tumor types. Although many anticancer therapies can alter tumor growth, in most cases the effect is not long lasting. Consequently, there is a significant need for new agents with low susceptibility to common drug resistance mechanisms in order to improve response rates and potentially extend survival. Approximately 30% of the women diagnosed with early-stage disease in turn progress to metastatic breast cancer, for which therapeutic options are limited. Current recommendations for first-line chemotherapy include anthracycline-based regimens and taxanes (paclitaxel and docetaxel). They typically give response rates of 30 to 70% but the responses are often not durable, with a time to progression of 6 to 10 months. Patients with progression or resistance may be administered capecitabine, gemcitabine, vinorelbine, albumin-bound paclitaxel, or ixabepilone, while other drugs are being evaluated. Response rates in this setting tend to be low (20 to 30%); the median duration of responses is <6 months and the results do not always translate into improved long-term outcomes. The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting. |
format | Text |
id | pubmed-2972556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29725562010-11-04 Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone Rivera, Edgardo Gomez, Henry Breast Cancer Res Proceedings Resistance to chemotherapy is a major obstacle to the effective treatment of many tumor types. Although many anticancer therapies can alter tumor growth, in most cases the effect is not long lasting. Consequently, there is a significant need for new agents with low susceptibility to common drug resistance mechanisms in order to improve response rates and potentially extend survival. Approximately 30% of the women diagnosed with early-stage disease in turn progress to metastatic breast cancer, for which therapeutic options are limited. Current recommendations for first-line chemotherapy include anthracycline-based regimens and taxanes (paclitaxel and docetaxel). They typically give response rates of 30 to 70% but the responses are often not durable, with a time to progression of 6 to 10 months. Patients with progression or resistance may be administered capecitabine, gemcitabine, vinorelbine, albumin-bound paclitaxel, or ixabepilone, while other drugs are being evaluated. Response rates in this setting tend to be low (20 to 30%); the median duration of responses is <6 months and the results do not always translate into improved long-term outcomes. The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting. BioMed Central 2010 2010-10-22 /pmc/articles/PMC2972556/ /pubmed/21050423 http://dx.doi.org/10.1186/bcr2573 Text en Copyright ©2010 Rivera and Gomez; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Proceedings Rivera, Edgardo Gomez, Henry Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone |
title | Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone |
title_full | Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone |
title_fullStr | Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone |
title_full_unstemmed | Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone |
title_short | Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone |
title_sort | chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone |
topic | Proceedings |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972556/ https://www.ncbi.nlm.nih.gov/pubmed/21050423 http://dx.doi.org/10.1186/bcr2573 |
work_keys_str_mv | AT riveraedgardo chemotherapyresistanceinmetastaticbreastcancertheevolvingroleofixabepilone AT gomezhenry chemotherapyresistanceinmetastaticbreastcancertheevolvingroleofixabepilone |